BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 20, 2026
Home » Authors » Amanda Lanier

Amanda Lanier

Articles

ARTICLES

Hand, stylus pointing at graph on screen
Index insights

M&A activity drives infectious disease stock rebound

Feb. 19, 2026
By Amanda Lanier
No Comments
Infectious disease-focused biopharma companies continued their rebound into year-end, with the BioWorld Infectious Disease Index finishing 2025 up 68.55% after standing at a collective 28.98% at the end of October. The rally underscores a sharp reversal from earlier in the year, when the index had declined 17.83% by the end of April before recovering to a 4.34% gain by July.
Read More
Med-tech deals January 2026

Med-tech deals and M&As start 2026 below last year’s norms

Feb. 17, 2026
By Amanda Lanier
No Comments
Med-tech M&A activity opened 2026 at a slower pace, with January deal value totaling $665.33 million, coming in well below the 2025 monthly average of $3.51 billion and trailing most individual months last year.
Read More
Deal handshake and arrows sketch on chalkboard
Biopharma deals January 2026

Strong start to 2026 signals continued momentum in biopharma deals

Feb. 13, 2026
By Amanda Lanier
No Comments
Biopharma dealmaking continued its momentum into 2026, with January logging $31.16 billion in total value. That figure outpaced January 2025’s $28.63 billion and exceeded the 2025 monthly average of $24.38 billion. In addition, January 2026 ranks as the highest first month in the past eight years.
Read More
IPO, coins, upward arrow
Med-tech IPO performance 2025

IPO window reopens, med-tech class of 2025 gains 26%

Feb. 12, 2026
By Amanda Lanier
No Comments
After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million raised in 2024 and a low-point of $110 million in 2023.
Read More
Hand holding dollar sign
Biopharma financings January 2026

2026 kicks off with $10.8B January financing haul

Feb. 10, 2026
By Amanda Lanier
No Comments
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.
Read More
Med-tech financings January 2026

Med-tech financing off to slow start with $1.52B raised in January

Feb. 9, 2026
By Amanda Lanier
No Comments
While in 2025 med-tech financings averaged $3.3 billion per month, January 2026 saw the sector bring in $1.52 billion across 39 transactions. It was the lowest monthly total since November 2024’s $924.59 million. However, a number of months last year saw fluctuating values, ranging from $1.65 billion in July to $8.26 billion in December 2025, indicating uncertainty as to how industry financings will shake out this year.
Read More
Hand holding dollar sign
Biopharma financings January 2026

2026 kicks off with $10.8B January financing haul

Feb. 6, 2026
By Amanda Lanier
No Comments
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.
Read More
Line graph arrow trending upward
Index insights

Cancer index surges 72% as Terns, Olema lead gains

Feb. 5, 2026
By Amanda Lanier
No Comments
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year featured standout gains, led by Terns Pharmaceuticals Inc., which surged 620%.
Read More
Syringe and capsules atop lab chart
Biopharma clinical updates December 2025

Phase III wins propel Capricor, Belite and DBV higher in December

Feb. 2, 2026
By Amanda Lanier
No Comments
BioWorld tracked 215 clinical trial readouts spanning phases I through III in December 2025, a sizeable increase from 170 updates in November, but below the 252 reported in October.
Read More
Financial line graph
Index insights

Arrowhead gains, Agios drops as drug developers end 2025 up 34%

Jan. 30, 2026
By Amanda Lanier
No Comments
After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs.
Read More
View All Articles by Amanda Lanier

Popular Stories

  • Today's news in brief

    BioWorld
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing